EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21

John J Schellenberg, Heather J Adam, Melanie R Baxter, James A Karlowsky, Alyssa R Golden iD, Irene Martin, George G Zhanel iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von John J Schellenberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada R…. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Infections, Serogroup, Microbial Sensitivity Tests. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Manitoba, Shared Health, the National Microbiology Laboratory-Public Health Agency of Canada (PHAC-NML.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lower respiratory infections and invasive disease caused by Streptococcus pneumoniae serotype 3 remain major clinical challenges around the world, despite widespread availability of updated vaccines.

Methods

As part of CANWARD, antimicrobial susceptibility testing and serotyping were performed on all S. pneumoniae isolates from 2007 to 2021. A subset of 226/264 (85.6%) serotype 3 isolates were selected for WGS to determine sequence type (ST)/clonal cluster (CC) and correspondence of antimicrobial resistance determinants (erm, mefAE, tetM, cat, folA, folP) with resistance phenotype.

Results

Of the 3,039 S. pneumoniae isolates obtained from 2007 to 2021, 8.7% (n = 264) were serotype 3, with 64.0% of respiratory origin and 36.0% from blood. Of 226 sequenced serotype 3 isolates, 184 (81.4%) were ST180 (GPSC12). The proportion of ST8561 (single locus variant of ST180) increased from 7.2% to 16.6% during the study period. An increasing proportion of serotype 3 isolates had phenotypic resistance (P = 0.0007) and genetic resistance determinants (P = 0.004), comparing 2017–21 to 2007–11, largely due to a recently expanded ST180 clade with cat, tetM and mef determinants.

Conclusions

S. pneumoniae serotype 3 from GPSC12 continues to dominate throughout Canada, with an increase in the proportion of ST8561. The proportion of serotype 3 isolates that are phenotypically resistant and with genetic resistance determinants is increasing over time, reflecting a global increase in GPSC12 genotypes with known resistance determinants. Phylogenomic characterization of isolates collected over time and from around the world may facilitate improved treatment and enhanced prevention strategies, including new vaccines with activity against S. pneumoniae serotype 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus pneumoniaePneumococcal InfectionsSerogroupMicrobial Sensitivity TestsAnti-Bacterial AgentsWhole Genome SequencingHumansCanadaChild, PreschoolChildAdolescentYoung AdultInfantAdultFemaleMiddle AgedMaleAgedPhenotypeSerotypingRespiratory Tract InfectionsAged, 80 and overDrug Resistance, BacterialGenotypeMultilocus Sequence Typing

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0J9.
  • Clinical Microbiology, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9.
  • National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2.

ORCID-Profile: Alyssa R Golden, George G Zhanel

Förderung

  • University of Manitoba
  • Shared Health
  • the National Microbiology Laboratory-Public Health Agency of Canada (PHAC-NML
  • Merck Canada, Inc
  • the National Microbiology Laboratory—Public Health Agency of Canada (PHAC-NML

Zitieren

APA

Schellenberg, J. J., Adam, H. J., Baxter, M. R., Karlowsky, J. A., Golden, A. R., Martin, I., & Zhanel, G. G. (2024). Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae272

Vancouver

Schellenberg JJ, Adam HJ, Baxter MR, Karlowsky JA, Golden AR, Martin I, et al. Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae272

BibTeX
@article{Schellenberg2024,
  author = {Schellenberg, John J and Adam, Heather J and Baxter, Melanie R and Karlowsky, James A and Golden, Alyssa R and Martin, Irene and Zhanel, George G},
  title = {Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae272}
}
Kostenlos starten →